Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Danaher Co. (NYSE:DHR). In a filing disclosed on March 27th, the Representative disclosed that they had sold between $15,001 and $50,000 in Danaher stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
- Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
- Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
- Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
- Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
- Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
- Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
- Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
- Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
- Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.
Danaher Price Performance
DHR stock traded down $4.43 on Friday, hitting $205.69. 2,388,883 shares of the company’s stock traded hands, compared to its average volume of 3,186,485. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a market cap of $147.01 billion, a price-to-earnings ratio of 38.96, a P/E/G ratio of 2.66 and a beta of 0.82. Danaher Co. has a 1-year low of $196.80 and a 1-year high of $281.70. The stock has a fifty day moving average of $214.57 and a 200-day moving average of $236.90.
Danaher Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.32 dividend. The ex-dividend date is Friday, March 28th. This represents a $1.28 annualized dividend and a dividend yield of 0.62%. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s payout ratio is currently 24.24%.
Institutional Trading of Danaher
Large investors have recently modified their holdings of the company. Kentucky Retirement Systems Insurance Trust Fund grew its position in shares of Danaher by 11.6% in the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate’s stock valued at $4,874,000 after purchasing an additional 2,202 shares during the last quarter. ORG Partners LLC grew its holdings in Danaher by 1,212.8% in the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock valued at $636,000 after buying an additional 2,559 shares during the last quarter. Generate Investment Management Ltd acquired a new position in shares of Danaher during the fourth quarter worth approximately $8,044,000. Stifel Financial Corp boosted its position in shares of Danaher by 1.3% in the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after acquiring an additional 11,216 shares during the period. Finally, Compass Capital Management Inc. grew its stake in shares of Danaher by 4.8% in the fourth quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate’s stock worth $54,615,000 after acquiring an additional 10,994 shares during the last quarter. 79.05% of the stock is owned by institutional investors.
Insider Buying and Selling
In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 11.10% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
Several research firms have issued reports on DHR. Robert W. Baird cut their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target for the company in a research report on Friday, December 13th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Guggenheim initiated coverage on Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price for the company. Finally, Wells Fargo & Company lowered their price target on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $278.24.
Read Our Latest Analysis on DHR
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
- Five stocks we like better than Danaher
- Investing in Construction Stocks
- MarketBeat Week in Review – 03/24 – 03/28
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Stock Market Sectors: What Are They and How Many Are There?
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.